Early menopause: A hazard to a woman's health

Claudio Hernández-Angeles, Camil Castelo-Branco, Claudio Hernández-Angeles, Camil Castelo-Branco

Abstract

Early menopause or premature ovarian insufficiency (POI) is a common cause of infertility in women and affects about one per cent of young women. This disorder has significant psychological sequelae and major health implications. Its relevance has increased in recent years due to the fact that age of motherhood is being delayed in developed countries, with the risk of having either primary ovarian insufficiency or less possibilities of pregnancy. The main characteristics are absence of ovulation, amenorrhoea and high levels of serum gonadotropins (hypergonadotropic hypogonadism). Although the aetiology remains uncertain in most cases, several rare specific causes have been elucidated. Potential causes for POI are iatrogenic (ovarian surgery, radiotherapy or chemotherapy), environmental factors, viral infections, metabolic and autoimmune diseases, and genetic alterations. Because of the association with other autoimmune diseases, close follow up is recommended in patients with POI. The traditional indicators to evaluate ovarian ageing are age, serum hormonal levels, anti-Mullerian hormone, antral follicle count, and ultrasonography of ovaries. Hormone replacement therapy remains the mainstay of treatment, and the best chance of achieving a pregnancy is through oocyte donation. This article aims to present an overview of potential causes, clinical manifestations, and treatment options of POI.

References

    1. Emre SY, Balik KI, Bauthan O. Ovarian aging and premature ovarian failure. J Turk Ger Gynecol Assoc. 2014;15:190–6.
    1. Fenton AJ. Premature ovarian insufficiency: Pathogenesis and management. J Midlife Health. 2015;6:147–53.
    1. Atria A. Early menopause and hormone therapy. Rev Med Chil. 1950;78:373–7.
    1. Pouresmaelli F, Fazeli Z. Premature ovarian failure: A critical condition in the reproductive potential with various genetic causes. Int J Fertil Steril. 2014;8:1–12.
    1. World Health Organization (WHO). Research on the menopause in the 1990s. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1996;866:1–107.
    1. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97:1159–68.
    1. Jin M, Yu YQ, Huang HF. An update on primary ovarian insufficiency. Sci China Life Sci. 2012;55:677–86.
    1. Visser JA, Schipper I, Laven JS, Themmen AP. Anti-Mullerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol. 2012;8:331–41.
    1. Younis JS. Ovarian aging and implications for fertility female health. Minerva Endocrinol. 2012;37:41–57.
    1. Practice Committee of American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103:e9–19.
    1. Kovanci E, Schutt AK. Premature ovarian failure: clinical presentation and treatment. Obstet Gynecol Clin North Am. 2015;42:153–61.
    1. Fortuño C, Labarta E. Genetics of primary ovarian insufficiency: a review. Assist Reprod Genet. 2014;31:1573–85.
    1. Wood MA, Rajkovic A. Genomic markers of ovarian reserve. Semin Reprod Med. 2013;31:399–415.
    1. Grive KJ, Freiman RN. The developmental origins of the mammalian ovarian reserve. Development. 2015;142:2554–63.
    1. Finch CE. The menopause and aging, a comparative perspective. J Steroid Biochem Mol Biol. 2014;142:132–41.
    1. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004;428:145–50.
    1. Crawford NM, Steiner AZ. Age-related infertility. Obstet Gynecol Clin North Am. 2015;42:15–25.
    1. Andreu-Vieyra C, Lin YN, Matzuk MM. Mining the oocyte transcriptome. Trends Endocrinol Metab. 2006;17:136–43.
    1. Hale GE, Robertson DM, Burger HG. The perimenopausal woman: endocrinology and management. J Steroid Biochem Mol Biol. 2014;142:121–31.
    1. Soni M, Hogervorst E. Premature ovarian insufficiency and neurological function. Minerva Endocrinol. 2014;39:189–99.
    1. deKoning CH, McDonell J, Themmen AP, de Jong FH, Homburg R, Lambalk CB. The endocrine and follicular growth dynamics throughout the menstrual cycle in women with consistently or variably elevated early follicular phase FSH compared with controls. Hum Reprod. 2008;23:1416–23.
    1. Chapman C, Cree L, Shelling AN. The genetics of premature ovarian failure: current perspectives. Int J Womens Health. 2015;23:799–810.
    1. Goswami D, Conway GS. Premature ovarian failure. Hum Reprod Update. 2005;11:391–410.
    1. Jiao X, Qin C, Li J, Qin Y, Gao X, Zhang B, et al. Cytogenetic analysis of 531 Chinese women with premature ovarian failure. Hum Reprod. 2012;21:2201–7.
    1. Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol. 2008;68:499–509.
    1. Gleicher N, Weghofer A, Barad DH. A pilot study of pre- mature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Müllerian hormone. Fertil Steril. 2009;91:1700–6.
    1. Wittenberger MD, Hagerman RJ, Sherman SL, McConkie-Rosell A, Welt CK, Rebar RW, et al. The FMR1 premutation and reproduction. Fertil Steril. 2007;87:456–65.
    1. Murray A, Ennis S, Morton N. No evidence for parent of origin influencing premature ovarian failure in fragile X premutation carriers. Am J Hum Genet. 2000;67:253–4.
    1. Baronchelli S, Villa N, Redaelli S, Lissoni S, Saccheri F, Panzeri E, et al. Investigating the role of X chromosome breakpoints in premature ovarian failure. Mol Cytogenet. 2012;5:32.
    1. Toniolo D, Rizzolio F. X chromosome and ovarian failure. Semin Reprod Med. 2007;25:264–71.
    1. Powell CM, Taggart RT, Drumheller TC, Wangsa D, Qian C, Nelson LM, et al. Molecular and cytogenetic studies of an Xi; autosome translocation in a patient with premature ovarian failure and review of the literature. Am J Med Genet. 1994;52:19–26.
    1. Bilgin EM, Covanci E. Gentics of premature ovarian failure. Curr Opin Obstet Gynecol. 2015;27:167–74.
    1. Viggiano E, Marabotti A, Burlina AP, Cazzorla C, D’Apice MR, Giordano L, et al. Clinical and molecular spectra in galactosemic patients from neonatal screening in northeastern Italy: structural and functional characterization of new variations in the galactose-1-phosphate uridyltransferase (GALT) gene. Gene. 2015;559:112–8.
    1. Timson DJ. The molecular basis of galactosemia - Past, present and future. Gene. 2015 pii: S03781119(15) 00801-X.
    1. van Erven B, Gubbels CS, van Golde RJ, Dunselman GA, Derhaag JG, de Wert G, et al. Fertility preservation in female classic galactosemia patients. Orphanet J Rare Dis. 2013;8:107.
    1. Ryan EL, Lynch ME, Taddeo E, Gleason TJ, Epstein MP, Fridovich-Keil JL. Cryptic residual GALT activity is a potential modifier of scholastic outcome in school age children with classic galactosemia. J Inherit Metab Dis. 2013;36:1049–61.
    1. Di Giacomo M, Barchi M, Baudat F, Edelmann W, Keeney S, Jasin M. Distinct DNA-damage-dependent and independent response drive the loss of oocytes in recombination-defective mouse mutants. Proc Natl Acad Sci Usa. 2005;102:737–42.
    1. Sonigo C, Sermondade N, Benard J, Benoit A, Shore J, Sifer C, et al. The past, present and future of fertility preservation in cancer patients. Future Oncol. 2015 Sep 11; [Epub ahead of print]
    1. Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian faiure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys. 2005;62:738–44.
    1. Meirow D, Dor J, Kauffman B, Shrim A, Rabinovici J, Schiff E, et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod. 2007;22:1622–33.
    1. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2011;11:CD008018.
    1. Castelo-Branco C, Nomdedeu B, Camus A, Mercadal S, Martínez de Osaba MJ, Balasch J. Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril. 2007;87:702–5.
    1. Mahajan N. Fertility preservation in female cancer patients: An overview. J Hum Reprod Sci. 2015;8:3–13.
    1. Castelo-Branco C, Rabanal A, Nomdedeu B, Durán M, Arigita M, Balasch J. Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies. Fertil Steril. 2009;92:1260–3.
    1. Dechanet C, Brunet C, Anahory T, Hamamah S, Hedon B, Dechaud H. Effects of cigarette smoking on female reproduction: from oocyte to embryo (Part I) Gynecol Obstet Fertil. 2011;39:559–66.
    1. La Marca A, Brozzeti A, Sighninolfi G, Marzotti S, Volpe E, Falorni A. Primary ovarian insufficiency: autoimmune causes. Curr Opin Obstet Gynecol. 2010;22:277–82.
    1. Silva CA, Yamakami LYS, Aikawa NE, Araujo DB, Carvalho JF, Bonfà E. Autoinmuneprmary ovarian insufficiency. Autoinm Rev. 2014;13:427–30.
    1. Carp HJ, Selmi C, Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. J Autoimmun. 2012;38:J266–74.
    1. Welt CK. Autoimmune oophoritis in the adolescent. Ann N Y Acad Sci. 2008;1135:118–22.
    1. Wémeau JL, Proust-Lemoine E, Ryndak A, Vanhove L. Thyroid autoimmunity and polyglandular endocrine syndromes. Hormones (Athens) 2013;12:39–45.
    1. Dragojević-Dikić S, Marisavljević D, Mitrović A, Dikić S, Jovanović T, Janković-Raznatović S. An immunological insight into premature ovarian failure (POF) Autoimmun Rev. 2010;9:771–4.
    1. Euthymiopoulou K, Aletras AJ, Ravazoula P, Niarakis A, Daoussis D, Antonopoulos I, et al. Antiovarian antibodies in primary Sjogren's syndrome. Rheumatol Int. 2007;27:1149–55.
    1. Bakalov VK1, Anasti JN, Calis KA, Vanderhoof VH, Premkumar A, Chen S, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46, XX spontaneous premature ovarian failure. Fertil Steril. 2005;84:958–65.
    1. Haller-Kikkatalo K, Salumets A, Uibo R. Review on autoimmune reactions infemale infertility: antibodies to follicle stimulating hormone. Clin Dev Immunol. 2012;2012:1–15.
    1. Wang H, Chen H, Qin Y, Shi Z, Zhao X, Xu J, et al. Risks associated with premature ovarian failure in Han Chinese women. Reprod Biomed Online. 2015;30:401–7.
    1. Ebrahimi M, Akbari AF. Pathogenesis and causes of premature ovarina failure. An update. Int J Fertl Steril. 2011;5:54–65.
    1. Ohl J, Partisani M, Demangeat C, Binder-Foucard F, Nisand I, Lang JM, et al. Alterations of ovarian reserve tests in Human immunodeficiency virus (HIV)-infected women. Gynecol Obstet Fertil. 2010;38:313–7.
    1. Panay N, Kalu E. Management of premature ovarian failure. Best Prac Res Clin Obstet Gynecol. 2009;23:129–40.
    1. Sassarini J, Lumsden MA, Critchley HOD. Sex hormone replacement in ovarian failure-new treatment concepts. Best Pract Res Clin Endocrinol Metab. 2015;29:105–14.
    1. Paterson WF, Hollman AS, Donaldson MD. Poor uterine development in Turner syndrome with oral oestrogen therapy. Clin Endocrinol. 2002;56:359–65.
    1. Castelo-Branco C. Management of Turner syndrome in adult life and beyond. Maturitas. 2014;79:471–5.
    1. Bidet M, Bachelot A, Bissauge E, Golmard JL, Gricourt S, Dulon J, et al. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. J Clin Endocrinol Metab. 2011;96:3864–72.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する